Compare INVZ & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVZ | NKTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Israel | United States |
| Employees | 415 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.1M | 247.4M |
| IPO Year | N/A | 2020 |
| Metric | INVZ | NKTX |
|---|---|---|
| Price | $0.68 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.68 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 2.1M | 960.2K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.61 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $1.63 |
| 52 Week High | $2.54 | $3.65 |
| Indicator | INVZ | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 58.40 |
| Support Level | $0.61 | $1.88 |
| Resistance Level | $0.72 | $3.65 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 51.44 | 49.64 |
Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.